Selvita S.A. Acquires PozLab

May 7, 2024

Selvita S.A. has completed the acquisition of 100% of the shares in PozLab, a Poznan-based CDMO providing drug product development, analytical and microbiological testing, and small pilot plant manufacturing under GMP. The deal expands Selvita's service offering beyond preclinical research into small-molecule drug manufacturing for early-stage clinical trials and strengthens its position in the pharmaceutical research value chain.

Buyers
Selvita S.A.
Targets
PozLab
Industry
Pharmaceuticals
Location
Greater Poland Voivodeship, Poland
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.